ArticleJournal of pregnancy2013
The heart-placenta axis in the first month of pregnancy: induction and prevention of cardiovascular birth defects.
Article in Journal of pregnancy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Birthweight and isolated congenital heart defects - A systematic review and meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2022Pooled it
- Maternal Blood as a Window to the Fetal Heart: Novel Biomarkers for Early Detection of Septal Defects.Biomedicines · 2026Review
- Non-coding RNAs in congenital heart disease and placental development: Bridging molecular mechanisms to clinical biomarkers and therapies.Non-coding RNA research · 2026Review
- Multi-omic insights of preeclampsia and cardiovascular health outcomes.Communications medicine · 2025Review
- Unmasking the Placenta-Heart Axis: A Comprehensive Review of Placental Abnormalities in Congenital Heart Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Placental Pathology and Placental Growth Factor (PlGF)/Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Pathway Expression Evaluation in Fetal Congenital Heart Defects.Life (Basel, Switzerland) · 2025Article
- Placental extracellular vesicles promote cardiomyocyte maturation and fetal heart development.Communications biology · 2024Article
- Folic Acid and Selected Risk Factors for Fetal Heart Defects-Preliminary Study Results.Nutrients · 2024Article
- Prenatal exposure to air pollutants and the risk of congenital heart disease: a Korean national health insurance database-based study.Scientific reports · 2024Article
- Advanced magnetic resonance imaging detects altered placental development in pregnancies affected by congenital heart disease.Scientific reports · 2024Article
- Advanced magnetic resonance imaging detects altered placental development in pregnancies affected by congenital heart disease.Research square · 2024Article
- The Relationship Between Placental Pathology and Neurodevelopmental Outcomes in Complex Congenital Heart Disease.Pediatric cardiology · 2023Article
- Second Trimester Fetal Cardiac Screening - Current Opinion.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023Article
- Analysis of commonly expressed genes between first trimester fetal heart and placenta cell types in the context of congenital heart disease.Scientific reports · 2022Article
- Placental DNA Methylation Abnormalities in Prenatal Conotruncal Heart Defects.Frontiers in genetics · 2022Article
- Preeclampsia and Fetal Congenital Heart Defects.Current cardiology reviews · 2022Review
- Adhesion G protein-coupled receptor Gpr126/Adgrg6 is essential for placental development.Science advances · 2021Article
- Placental abnormalities in congenital heart disease.Translational pediatrics · 2021Review
- Review
- Fetal brain issues in congenital heart disease.Translational pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrapolating from animal studies to human pregnancy, our studies showed that folate (FA) deficiency as well as one-time exposure to environmental factors in the first two to three weeks of human gestation can result in severe congenital heart defects (CHDs). Considering that approximately 49% of pregnancies are unplanned, this period of pregnancy can be considered high-risk for cardiac, as well as for neural, birth defects, as the woman usually is not aware of her pregnancy and may not yet be taking precautionary actions to protect the developing embryo. Using avian and mouse vertebrate models, we demonstrated that FA supplementation prevents CHD induced by alcohol, lithium, or elevation of the metabolite homocysteine, a marker for FA deficiency. All three factors affected the important Wnt signaling pathway by suppressing Wnt-mediated gene expression in the heart fields, resulting in a delay of cardiomyocyte migration, cardiomyogenesis, and CHD. Optimal protection of cardiogenesis was observed to occur with FA supplementation provided upon morning after conception and at higher doses than the presently available in prenatal vitamin supplementation. Our studies demonstrate pathways and cell processes that are involved with protection of one-carbon metabolism during heart development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.